MedPath
NMPA Approval

Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed

国药准字SJ20150033

August 13, 2020

S20150033

Drug Information

吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗

潘太欣

注射剂

本品为两个包材包装,其一为百白破脊髓灰质炎疫苗,混悬液,每支0.5ml;其二为b型流感嗜血杆菌结合疫苗,冻干粉。使用前两者混合。其中百白破脊髓灰质炎疫苗含:无细胞百日咳疫苗效价不低于4.0IU;白喉疫苗效价不低于30IU;破伤风疫苗效价不低于40IU;1型灭活脊髓灰质炎病毒40DU,2型灭活脊髓灰质炎病毒8DU,3型灭活脊髓灰质炎病毒32DU;b型流感嗜血杆菌结合疫苗含与破伤风类毒素结合的b型流感嗜血杆菌多糖10μg。

生物制品

August 13, 2020

August 12, 2025

Company Information

Applicant Company

SANOFI PASTEUR

14 Espace Henry Vallee 69007 LYON, France

Manufacturing Company

SANOFI PASTEUR

1541 avenue Marcel Merieux, 69280 MARCY L'ETOILE, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗 - NMPA 批准文号 | MedPath